Press Release

GPT Healthcare Limited Regd. Office: GPT Centre, JC-25, Sector III, Salt Lake, Kolkata – 700 106, India CIN : L70101WB1989PLC047402 Phone : +91-33-4050-7000, Email : info@gptgroup.co.in , Visit us: www.gptgroup.co.in GPTHEALTH/CS/SE/2026-27 November 5, 2026 The Department of Corporate Services National Stock Exchange of India Limited BSE Limited, Exchange Plaza, Plot no. C/1, G Block, Phiroze Jeejeebhoy Towers, Bandra-Kurla Complex, Bandra (E), Dalal Street Mumbai - 400 051 Mumbai – 400001 Scrip Symbol: GPTHEALTH Scrip Code: 544131 ISIN: INE486R01017 Dear Sir/Madam Sub: Press Release on Un-Audited Financial Results for the 2nd quarter and half year ended September 30, 2026: In compliance with Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the Company’s Code of Practices and Procedure for Fair Disclosure of Unpublished Price Sensitive Information, kindly find enclosed herewith a press release on the Un-Audited Financial Results for the 2nd quarter and half year ended September 30, 2026. Kindly take the aforesaid information on record and oblige. Thanking You, Yours sincerely, For GPT Healthcare Limited Ankur Sharma Company Secretary and Compliance Officer M. No A31833 Encl. As Above. GPT HEALTHCARE LIMITED Total Income for H1FY27 stood at Rs 267 crore a growth of 16.5% y-o-y Kolkata, November 5th , 2026: GPT Healthcare Limited (GPT) (BSE: 544131 ; NSE: GPTHEALTH) reported its unaudited financial result for the quarter ended September 30, 2026. H1 FY27 Total Income EBITDA PAT 266.8 Cr (16.5%) 56.0 Cr (30.3%) 28.1 Cr (53.9%) Key Financial Highlights : Q2 & H1FY27 Particulars (Rs. Crs) Q2FY27 Q2FY26 Y-o-Y Q1FY27 Q-o-Q H1FY27 H1FY26 Y-o-Y Total Income 138.6 120.2 15.2% 128.2 8.1% 266.8 228.9 16.5% EBITDA 29.8 24.1 23.9% 26.2 13.8% 56.0 43.0 30.3% EBITDA Margin (%) 21.5% 20.0% 20.4% 21.0% 18.8% Profit After Tax 15.4 10.6 45.2% 12.7 21.0% 28.1 18.3 53.9% PAT Margin (%) 11.1% 8.8% 9.9% 10.5% 8.0% Key Operational Highlights for Q2 & H1FY27: • In Q2FY27, Company maintained a competitive and affordable ARPOB of ₹40,721, registering 7.1% YoY growth. Occupancy improved to 50.3% across the hospital network, including the newly operationalised Raipur facility, reflecting higher patient volumes and improved capacity utilisation. • EBITDA Margin Improved by 150 bps YoY to 21.5% in Q2 FY27. For H1 FY27, EBITDA margin expanded by 221 bps to 21.0% from 18.8%. • ILS Dum Dum, along with ILS Raipur, has collectively performed over 750 renal transplants • ILS Howrah with MAKO robot, nearing 100 robotics. • ILS Agartala delivered over 3200 radiation therapy procedures. • ILS Salt Lake surpassed 850 robotic surgeries. • Jamshedpur hospital remains on track for completion by Q4 FY27. GPT HEALTHCARE LIMITED Commenting on the performance, GPT Healthcare Chairman, Dr. Om Tantia, said: “GPT Healthcare delivered another quarter of strong performance, supported by disciplined execution, improving operational metrics and a stronger contribution from mature hospitals. Total income grew 16.5% YoY, driven by resilient performance across established facilities, alongside the gradual ramp-up of newer hospitals. Network occupancy improved to 47.9% in H1 FY27, compared with 44.7% in H1 FY26, supported by higher patient volumes, improved throughput and better utilisation of the hospital network. Inpatient revenue grew by 16.4% YoY, while outpatient revenue increased by 13.5% YoY, reflecting healthy growth across both patient segments. Meanwhile, ARPOB increased by 8.1% YoY to ₹41,490, driven by improved realisations and a stronger specialty mix. Going forward, the Company remains focused on unlocking operating leverage, expanding its footprint, strengthening advanced clinical capabilities and adopting an asset-light expansion model. With a clear focus on capacity utilisation, speciality diversification and disciplined growth” About GPT Healthcare Limited (GPT): GPT Healthcare Limited is listed on National Stock Exchange of India Limited and BSE Limited under Symbol: GPTHEALTH, and Scrip Code: 544131, respectively. GPT Healthcare Limited, the healthcare arm of the GPT Group, operates the ILS Hospitals brand, a leading neighbourhood tertiary-care hospital platform in Eastern India. Established in 2000, the Company currently owns and operates five multi-specialty hospitals—at ILS Salt Lake (85 bed), ILS Agartala (205 bed), ILS Dumdum (155 bed), ILS Howrah (116 bed), and ILS Raipur (158 bed)—each equipped with modern infrastructure and comprehensive clinical capabilities that enable the delivery of end-to-end medical solutions. Collectively, the network commands a capacity of over 719 beds across key Eastern Indian markets, strategically located within high-density residential catchments, while consistently maintaining its affordable care positioning. The Company follows a proximity-based, capital-efficient operating model designed to enhance accessibility, enable faster occupancy ramp-up, and ensure strong control over clinical outcomes and operating metrics. Its hospitals offer advanced tertiary care services across key specialties including oncology, cardiology, renal transplants, and robotic surgeries, underpinned by standardized clinical governance, robust operating processes, and experienced medical leadership. For more information about the company, please visit: http://www.ilshospitals.com For further information, contact: GPT Healthcare Ltd | Phone: +91 33 4050 7000 | Email: ghl.cosec@gptgroup.co.in GPT HEALTHCARE LIMITED Safe Harbor Certain statements in this communication may be ‘forward-looking statements within the meaning of applicable laws and regulations. These forward-looking statements involve several risks, uncertainties, and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. Important developments that could affect the Company’s operations include changes in the industry structure, significant changes in the political and economic environment in India and overseas, tax laws, import duties, litigation, and labour relations. GPT Healthcare Limited will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances. COMPANY : INVESTOR RELATIONS ADVISORS : Ms. Pooja Swami pooja.swami@cygnuspartners.in ir@gptgroup.co.in Ms. Mamta Nehra CIN : L70101WB1989PLC047402 Mamta.nehra@cygnuspartners.in